论文部分内容阅读
目的:为了对比两种内固醇激素—甲基强的松龙琥珀酸钠和氢化可的松在重症哮喘中的治疗价值。方法:随机开放比较了35例甲基强的松龙琥珀酸钠200mg静脉滴注和39例氢化可的松200mg静脉滴注,两药均每日2～3次应用。结果:治疗3日后二组患者总的临床疗效和PEF％预计值的改善程度无明显差别,但35例接受甲基强的松龙琥珀酸钠治疗患者在治疗第1、2天PEF％预计值的改善幅度和治疗第1天达到临床控制和显效的人数明显高于39例接受氢化可的松治疗的患者。结论:甲基强的松龙琥珀酸钠在缓解重症哮喘患者气道阻塞,改善是临床症状方面的应用价值优于氢化可的松。
Objective: To compare the therapeutic value of two steroid hormones, methylprednisolone sodium succinate and hydrocortisone, in severe asthma. Methods: 35 cases of methylprednisolone sodium succinate 200 mg intravenous drip and 39 cases of hydrocortisone 200 mg intravenous drip were compared randomly. Both drugs were applied twice or three times a day. Results: After 3 days of treatment, there was no significant difference between the two groups in the overall clinical efficacy and the improvement of PEF% predicted value. However, 35 cases of patients receiving methylprednisolone sodium succinate treatment at the first and second days of treatment PEF% predicted The magnitude of improvement and the number of patients achieving clinically significant and effective treatment on day 1 were significantly higher than those in 39 patients treated with hydrocortisone. CONCLUSION: Methylprednisolone sodium succinate is superior to hydrocortisone in relieving airway obstruction and improving clinical symptoms in patients with severe asthma.